Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 4/20 | 0.44 |
| ▸ | TOP2A | P11388 | 6/20 | 0.44 |
| ▸ | TOP2B | Q02880 | 6/20 | 0.44 |
| ▸ | GSK3B | P49841 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | CLK2 | P49760 | 1/20 | 0.43 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL585353 | 1.00 | KCNH2 (0.44) | KCNH2TOP2ATOP2BGSK3BKDM4E | |
| SCHEMBL2845820 | 1.00 | KCNH2 (0.44) | KCNH2TOP2ATOP2BGSK3BKDM4E | |
| SCHEMBL584971 | 0.91 | ADRB2 (0.47) | KCNH2TOP2ATOP2BGSK3BKDM4E | |
| SCHEMBL584970 | 0.91 | ADRB2 (0.47) | KCNH2TOP2ATOP2BGSK3BKDM4E | |
| SCHEMBL2838587 | 0.91 | ADRB2 (0.47) | KCNH2TOP2ATOP2BGSK3BKDM4E | |
| SCHEMBL2843254 | 0.90 | KCNH2 (0.41) | KCNH2TOP2ATOP2BGSK3BKDM4E | |
| SCHEMBL2843251 | 0.90 | KCNH2 (0.41) | KCNH2TOP2ATOP2BGSK3BKDM4E | |
| SCHEMBL585402 | 0.89 | STAT3 (0.43) | KCNH2TOP2ATOP2BGSK3BKDM4E | |
| SCHEMBL2837862 | 0.89 | STAT3 (0.43) | KCNH2TOP2ATOP2BGSK3BKDM4E | |
| SCHEMBL585401 | 0.89 | STAT3 (0.43) | KCNH2TOP2ATOP2BGSK3BKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222302-A1 | Novel Antibacterial Compounds | ACTELION PHARMACEUTICALS LTD (CH) | 2010-09-02 | — | — | US | claimed |
| EP-2102217-B1 | 4- (2-OXO-OXAZOLIDIN-3YL)-PHENOXYMETHYLE DERIVATIVEAS AS ANTIBACTERIALS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-02-15 | — | — | EP | disclosed |
| US-8039466-B2 | 5-hydroxymethyl-oxazolidin-2-one antibacterials | ACTELION PHARMACEUTICAL LTD. (CH) | 2011-10-18 | — | — | US | disclosed |
| EP-2256120-A1 | Oxazolidinone-quinolone hybrids as antibacterial compounds | Actelion Pharmaceuticals Ltd. (CH) | 2010-12-01 | — | — | EP | disclosed |
| US-20100222302-A1 | Novel Antibacterial Compounds | ACTELION PHARMACEUTICALS LTD (CH) | 2010-09-02 | — | — | US | disclosed |
| US-20100069376-A1 | 5-HYDROXYMETHYL-OXAZOLIDIN-2-ONE ANTIBACTERIALS | ACTELION PHARMACEUTICALS, LTD. (CH) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069376-A1 | 5-HYDROXYMETHYL-OXAZOLIDIN-2-ONE ANTIBACTERIALS | OGFOD1, ODC1, OXGR1 | KCNH2 594/4885TOP2A 3924/4885TOP2B 4680/4885 |
| US-20100222302-A1 | Novel Antibacterial Compounds | ODC1, AOC1, OGFOD1 | KCNH2 394/4885TOP2A 4672/4885TOP2B 4842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.